Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG antibodies bind CD4 on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting CD4+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG binds CD5 (among other T‑cell antigens) and induces complement-dependent cytotoxicity, Fc-mediated ADCC, and opsonization leading to phagocytic clearance of CD5+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG antibodies bind CD7 on T cells and induce complement-dependent lysis and Fc-mediated ADCC/opsonophagocytic clearance, depleting CD7+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG antibodies bind CD8α on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting CD8+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
YES
DIRECT
ATG contains antibodies that bind CD11a on T cells, leading to complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance of the bound cells.